Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Go back to Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis| (NASDAQ: IMUX) | Delayed: 15.07 +0.32 (2.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.75 | 52 Week High | $ | |||
| Open | $14.48 | 52 Week Low | $ | |||
| Day High | $15.41 | P/E | N/A | |||
| Day Low | $14.12 | EPS | $ | |||
| Volume | 224,468 | |||||
